Financial reports
10-K
2023 FY
Annual report
22 Mar 24
10-Q
2023 Q3
Quarterly report
7 Nov 23
10-Q
2023 Q2
Quarterly report
8 Aug 23
10-Q
2023 Q1
Quarterly report
12 May 23
10-K
2022 FY
Annual report
29 Mar 23
10-Q
2022 Q3
Quarterly report
8 Nov 22
10-Q
2022 Q2
Quarterly report
9 Aug 22
10-Q
2022 Q1
Quarterly report
10 May 22
Current reports
8-K
Departure of Directors or Certain Officers
19 Apr 24
8-K
Lyra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
21 Mar 24
8-K
Departure of Directors or Certain Officers
1 Mar 24
8-K
Regulation FD Disclosure
8 Jan 24
8-K
Entry into a Material Definitive Agreement
28 Dec 23
8-K
Amendments to Articles of Incorporation or Bylaws
18 Dec 23
8-K
Lyra Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
7 Nov 23
8-K
Other Events
12 Sep 23
8-K
Entry into a Material Definitive Agreement
1 Sep 23
8-K
Lyra Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
8 Aug 23
Registration and prospectus
S-8
Registration of securities for employees
22 Mar 24
S-3
Shelf registration
22 Mar 24
424B5
Prospectus supplement for primary offering
1 Sep 23
424B3
Prospectus supplement
7 Jul 23
S-3
Shelf registration
28 Jun 23
D
$50.00 mm in equity / options, sold $50.00 mm, 24 investors
9 Jun 23
S-8
Registration of securities for employees
29 Mar 23
424B3
Prospectus supplement
20 May 22
S-3
Shelf registration
11 May 22
D
$100.49M in equity / options, sold $100.49M, 34 investors
26 Apr 22
Proxies
PRE 14A
Preliminary proxy
19 Apr 24
DEFA14A
Additional proxy soliciting materials
25 Apr 23
DEF 14A
Definitive proxy
25 Apr 23
DEFA14A
Additional proxy soliciting materials
27 Apr 22
DEF 14A
Definitive proxy
27 Apr 22
DEFA14A
Additional proxy soliciting materials
14 Apr 21
DEF 14A
Definitive proxy
14 Apr 21
Other
EFFECT
Notice of effectiveness
2 Apr 24
EFFECT
Notice of effectiveness
10 Jul 23
CORRESP
Correspondence with SEC
6 Jul 23
UPLOAD
Letter from SEC
5 Jul 23
EFFECT
Notice of effectiveness
23 May 22
CORRESP
Correspondence with SEC
18 May 22
UPLOAD
Letter from SEC
17 May 22
EFFECT
Notice of effectiveness
21 May 21
CORRESP
Correspondence with SEC
18 May 21
UPLOAD
Letter from SEC
17 May 21
Ownership
4
Harlan Waksal
20 Mar 24
4
Maria Palasis
20 Mar 24
SC 13G/A
PURA VIDA INVESTMENTS, LLC
15 Feb 24
SC 13G/A
Venrock Healthcare Capital Partners II, L.P.
14 Feb 24
SC 13G/A
CITADEL ADVISORS LLC
14 Feb 24
SC 13G/A
Nantahala Capital Management, LLC
14 Feb 24
SC 13D/A
PERCEPTIVE ADVISORS LLC
14 Feb 24
SC 13G/A
Point72 Asset Management, L.P.
14 Feb 24
SC 13G
Vestal Point Capital, LP
13 Feb 24
4
John E Bishop
1 Feb 24